Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
about
Targeted drugs in small-cell lung cancerCellular and molecular biology of small cell lung cancer: an overviewNew and emerging developments in extensive-stage small cell lung cancer therapeuticsHarnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Current approaches to the treatment of metastatic brain tumours.O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.Small cell lung cancer: where do we go from here?Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in LungPrognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?1p/19q codeletion and RET rearrangements in small-cell lung cancer.Epigenetic aberrant methylation of tumor suppressor genes in small cell lung cancerCombined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.Therapies in the pipeline for small-cell lung cancer.Left behind? Drug discovery in extensive-stage small-cell lung cancer.Progress and challenges in the treatment of small cell lung cancer.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Second-line treatments of small-cell lung cancers.Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.[Advances in the Treatment of Relapsed Small Cell Lung Cancer].Current standards for clinical management of small cell lung cancer.MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.[Advanced research on circulating tumor cells in lung cancer].Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells
P2860
Q26767017-3CF422F3-0EFD-4360-9FEF-476D1DE42945Q26767029-1B0FFF97-C867-4143-A8E6-71072B4248FBQ28076304-23E4F467-AD9E-4B86-A582-6012FFEC1ECEQ30620556-C2BFE5AD-0EE6-4A0D-BC3A-8893C4BA6C1FQ33417537-22E13269-6C23-40C5-832C-A5C02B915C4AQ33696559-AE7B5F33-2A56-4316-A834-3C4B005957A1Q33846619-8D592BB3-2484-4FA6-836C-0C21332AA94BQ33872327-53260309-75D7-498D-931F-F0BBD34EDB7AQ33914197-1E6E9CB5-E868-4418-8656-C8C2603D73BBQ34000985-32EF4BE0-2532-4914-B77F-E073E35A9638Q34452827-85278C0E-A7F8-4C95-AB85-93BAD057E998Q35920833-3C8A9BF2-F5C6-46CB-8F6B-73DA732DF0CAQ36261945-52F97508-0739-418B-815D-2DD726040D81Q36265194-2FB526BF-045D-4E11-B78E-ED487A0388F4Q36811784-5689ED88-5E7D-454C-BAEF-DAA666711560Q37021313-ABF18BA9-BAC4-48FA-8A6A-CC405CF962D6Q37128022-E1C1FC50-0ED6-400C-8B9E-C6C0DFC5F625Q38369616-FEA1CF63-3C0A-4839-A442-4FDB9358AD1DQ38871386-A2C7DFC7-23BF-4A41-BDC7-53B2E4957F2CQ39250401-AD3F5C57-9F00-4535-BEE2-D56C66D2F16AQ39272825-23EE9EC4-1FE2-451D-AC9D-4AC5B9C4FA39Q39393217-5B2B5962-C8FC-4297-AC3B-D6B7CC2B41D4Q40640808-97B948E4-FD12-46E4-8518-7774912577C7Q47120183-06716B07-FD93-4B81-B3BC-E7BF443B01F7Q47789861-694C58CF-2D83-4187-99EC-93B3F2E1DF08Q50896526-E374EAE8-A05C-4E2E-A90E-74540C950E3DQ52657032-3DD08F02-FE3A-4B56-B021-CA09D56DEB77Q52932452-BF8C5F13-36AE-4DBB-AD7F-F0FE30EE7914Q53747313-CF338376-8091-4B4F-8DB6-23115C942CDDQ54953051-FE494051-2E2F-4664-B96B-2813E7F3A1F6Q55360749-8A20D8DD-84F6-4421-868F-7987ACBF6AABQ55464266-19476C86-0ECB-4A5E-BA65-C9881A0E2A7AQ58710931-A5BF8F39-5C53-4F8A-BB3C-39A60782964E
P2860
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II trial of temozolomide ...... rase as a potential biomarker.
@ast
Phase II trial of temozolomide ...... rase as a potential biomarker.
@en
type
label
Phase II trial of temozolomide ...... rase as a potential biomarker.
@ast
Phase II trial of temozolomide ...... rase as a potential biomarker.
@en
prefLabel
Phase II trial of temozolomide ...... rase as a potential biomarker.
@ast
Phase II trial of temozolomide ...... rase as a potential biomarker.
@en
P2093
P1476
Phase II trial of temozolomide ...... rase as a potential biomarker.
@en
P2093
Adriana Heguy
Andrei I Holodny
Camelia S Sima
Christopher G Azzoli
Dyana K Sumner
Gregory J Riely
John J Fiore
Kety Huberman
Kyuichi Kadota
Lee M Krug
P304
P356
10.1158/1078-0432.CCR-11-2059
P407
P50
P577
2012-01-06T00:00:00Z